汉森制药
(002412)
| 流通市值：32.71亿 | | | 总市值：33.06亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 269,286,565.75 | 1,004,469,462.29 | 693,981,713.71 | 480,445,782.48 |
| 营业收入 | 269,286,565.75 | 1,004,469,462.29 | 693,981,713.71 | 480,445,782.48 |
| 二、营业总成本 | 201,370,449.78 | 772,586,431.75 | 554,722,346.7 | 379,976,886.84 |
| 营业成本 | 63,041,529.3 | 242,530,924.48 | 172,562,813.76 | 121,991,256.39 |
| 税金及附加 | 4,434,140.16 | 20,047,571.17 | 13,963,958.48 | 9,580,968.74 |
| 销售费用 | 105,233,393.58 | 400,316,267.61 | 294,411,101.54 | 200,756,658.29 |
| 管理费用 | 19,079,881.93 | 68,800,805.13 | 45,119,863.61 | 27,595,557.35 |
| 研发费用 | 9,330,205.66 | 39,322,290.36 | 27,453,358.32 | 19,134,281.51 |
| 财务费用 | 251,299.15 | 1,568,573 | 1,211,250.99 | 918,164.56 |
| 其中:利息费用 | 571,625.02 | 2,561,280.63 | 2,023,105.59 | 1,492,700.03 |
| 其中:利息收入 | 280,039.98 | 1,299,590.08 | 1,082,521.94 | 770,518.44 |
| 加:公允价值变动收益 | 501,866.59 | 2,073,590.91 | 1,396,878.66 | 807,990.85 |
| 加:投资收益 | -45,279,555.05 | 9,972,397.05 | 4,740,181.17 | 11,810,076.16 |
| 资产减值损失(新) | 3,427.46 | -126,720.18 | -6,633.7 | 9,869.17 |
| 信用减值损失(新) | -1,681,797.57 | 359,091.21 | -1,713,877.95 | -1,787,330.39 |
| 其他收益 | 1,072,299.6 | 9,022,181.75 | 6,039,093.28 | 4,497,648.58 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,532,357 | 253,183,571.28 | 149,715,008.47 | 115,807,150.01 |
| 加:营业外收入 | 50,720.33 | 835,772.53 | 452,520.53 | 322,504.64 |
| 减:营业外支出 | 473,487.79 | 1,262,761.83 | 612,256.34 | 262,329.35 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 22,109,589.54 | 252,756,581.98 | 149,555,272.66 | 115,867,325.3 |
| 减:所得税费用 | 10,852,425.19 | 32,512,172.87 | 18,802,226.68 | 15,373,326.94 |
| 六、净利润 | 11,257,164.35 | 220,244,409.11 | 130,753,045.98 | 100,493,998.36 |
| 持续经营净利润 | 11,257,164.35 | 220,244,409.11 | 130,753,045.98 | 100,493,998.36 |
| 归属于母公司股东的净利润 | 11,257,164.35 | 220,244,409.11 | 130,753,045.98 | 100,493,998.36 |
| (一)基本每股收益 | 0.02 | 0.44 | 0.26 | 0.2 |
| (二)稀释每股收益 | 0.02 | 0.44 | 0.26 | 0.2 |
| 八、其他综合收益 | -21,337,283.83 | 20,108,712.37 | 7,490,193.67 | 14,068,081.35 |
| 归属于母公司股东的其他综合收益 | -21,337,283.83 | 20,108,712.37 | 7,490,193.67 | 14,068,081.35 |
| 九、综合收益总额 | -10,080,119.48 | 240,353,121.48 | 138,243,239.65 | 114,562,079.71 |
| 归属于母公司股东的综合收益总额 | -10,080,119.48 | 240,353,121.48 | 138,243,239.65 | 114,562,079.71 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-29 | 2024-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |